RESULTS OF PHASE II AMBRISENTAN TRIAL PUBLISHED

Myogen has announced the publication of the results from a Phase II trial of ambrisentan in patients with pulmonary arterial hypertension (PAH) in this month's issue of the Journal of the American College of Cardiology.

The publication concludes that ambrisentan appears to improve exercise capacity, symptoms and hemodynamics in patients with WHO class II to III PAH and that ambrisentan may have a very favorable efficacy-to-safety ratio in patients with PAH, including a low incidence and severity of serum aminotransferase abnormalities which does not appear to be dose-dependent.